-

ORPEA: Information on the Compensation and the Financial Conditions of the Departure of Mr. Philippe Charrier

PUTEAUX, France--(BUSINESS WIRE)--Regulatory News:

In the context of the departure of Mr. Philippe Charrier from ORPEA (Paris:ORP), effective July 28, 2022 following the annual general meeting, the Board of Directors of ORPEA acknowledged, on July 1,2022, the elements of compensation to which he is entitled in respect of the exercise of his functions during the financial year 2022 as Chairman of the Board of Directors, from January 1 to January 30, 2022 and then as of July 1, 2022, and as Chairman and Chief Executive Officer, from January 30 to June 30, 2022.

In his capacity as Chairman of the Board of Directors, Philippe Charrier receives a fixed annual remuneration of €260,000 pro rata temporis, i.e. an amount of €41,269.84 for 2022.

The compensation of Mr. Philippe Charrier, as Chief Executive Officer from January 30 to June 30, 2022, was composed only of a fixed annual remuneration of €760,000, given that he was appointed with the mission of ensuring, under the control of the Board of Directors, that best practices are applied throughout the company and of clarifying the allegations made, based in particular on the evaluation missions entrusted by the Board of Directors to the firms Grant Thornton and Alvarez & Marsal. It represents, pro rata temporis, an amount of 319,682.52 euros.

He also receives his compensation as a director.

Mr. Philippe Charrier does not receive, in his capacity as Chairman of the Board of Directors and Chief Executive Officer, any annual or long-term variable compensation (in particular no stock options or performance shares).

He does not receive any other compensation or benefits in kind.

In particular, Mr. Philippe Charrier will not receive any severance pay or non-compete indemnity in the context of the termination of his functions within ORPEA.

Pursuant to the compensation policy applicable to the Chairman of the Board of Directors and Chief Executive Officer submitted to the General Meeting of July 28, 2022, which provides for the possibility of granting Mr. Philippe Charrier an exceptional compensation in view of very specific circumstances justifying such compensation under certain cumulative conditions, the Board of Directors has decided, on the recommendations of its the Appointments and Remuneration Committee and subject to approval of such compensation policy, to grant Mr. Philippe Charrier an exceptional compensation.

The Board of Directors wishes to reward the exceptional mobilization of Mr. Philippe Charrier, who has enabled the Group, to face major financing challenges, to announce the conclusion and approval of a conciliation protocol with its core banking pool, thus organizing the first stage in the restructuring of the Group’s financing strategy and enabling it to obtain new financing sources.

Alongside the in-depth audits conducted since February 2022, the identification and implementation of the first corrective measures and the organization throughout France of the Etats Généraux du Grand Age, Mr. Philippe Charrier successfully led the recruitment process for the new Chief Executive Officer in an unprecedented and particularly uncertain context. With the appointment of Mr. Laurent Guillot, who has taken office on July 1, 2022, the Group will be able to embark on a new stage and launch its in-depth transformation process.

To ensure alignment with the interest of shareholders, this exceptional compensation would take the form of an allocation of existing ORPEA shares1 representing, based on the closing price of the ORPEA share on June 30, 2022, 100% of the annual fixed compensation of Mr. Philippe Charrier as Chairman and Chief Executive Officer, pro rata temporis, which corresponds to 13,755 shares.

Pursuant to Article L. 22-10-34 of the French Commercial Code, the payment of this exceptional compensation is conditional upon the approval by the Shareholders' Meeting of July 28, 2022 of the compensation awarded in respect of and/or paid during fiscal year 2022 to Philippe Charrier.

About ORPEA (www.orpea-corp.com)

Founded in 1989, ORPEA is one of the world leaders in Dependency care (nursing homes, assisted living, post-acute and rehabilitation hospitals, mental health hospitals, home care services)

ORPEA is listed on Euronext Paris (ISIN code: FR0000184798) and is a member of the SBF 120, STOXX 600 Europe, MSCI Small Cap Europe and CAC Mid 60 indices.

____________

1

Treasury shares held by ORPEA.

 

Contacts

Investor Relations Director
ORPEA
Benoit Lesieur
Investor Relations Director
b.lesieur@orpea.net

Investor Relations
NewCap
Dusan Oresansky
Tel.: +33 (0)1 44 71 94 94
orpea@newcap.eu

Media Relations
Image 7
Charlotte Le Barbier
Tel.: +33 (0)6 78 37 27 60
clebarbier@image7.fr

Laurence Heilbronn
Tel.: 06 89 87 61 37
lheilbronn@image7.fr

ORPEA

BOURSE:ORP

Release Versions

Contacts

Investor Relations Director
ORPEA
Benoit Lesieur
Investor Relations Director
b.lesieur@orpea.net

Investor Relations
NewCap
Dusan Oresansky
Tel.: +33 (0)1 44 71 94 94
orpea@newcap.eu

Media Relations
Image 7
Charlotte Le Barbier
Tel.: +33 (0)6 78 37 27 60
clebarbier@image7.fr

Laurence Heilbronn
Tel.: 06 89 87 61 37
lheilbronn@image7.fr

More News From ORPEA

emeis: Half-Year Review (H2 2025) of the Liquidity Agreement Entered Into with Natixis Oddo BHF

PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: Under the liquidity agreement entrusted by emeis (Paris:EMEIS) (the “Company”) to Natixis Oddo BHF, the following resources were recorded in the dedicated liquidity account as of 31 December 2025. - 70,965 shares - €1,111,687 in cash During the 2025 second half-year, it was carried out a total of: PURCHASE 1,513 transactions 1,158,608 shares €15,241,520.04 SALE 1,604 transactions 1,165,917 shares €15,456,925.47 It is reminded that as of the las...

emeis Raises €3.15 Billion in New Financing

PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: emeis (Paris:EMEIS) finalized the raising of new financing totaling €3.15 billion with its banking partners and financial investors, based on the agreements in principle announced in a press release on November 10, 2025. A total of €3.15 billion in new financing with an average maturity of 5.5 years and an average margin on EURIBOR of 247 basis points2. This new financing breaks down as follows: €2.2 billion in term loans (Tranche 1) with a mat...

De-leveraging continues: emeis sells its nursing home business in Switzerland for nearly €270 million

PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: emeis (Paris:EMEIS) has finalized sales agreements with Tertianum, a Swiss operator specializing in care and support for the elderly, and two institutional real estate investors. These agreements cover nursing home activities in Switzerland and the associated real estate assets, for a total value of CHF 250 million1, or nearly €270 million. This new transaction brings the volume of disposals completed or secured since mid-2022 to nearly €2.4 bi...
Back to Newsroom